Calcium alterations in Alzheimer's disease: Pathophysiology, models and therapeutic opportunities

Pharmacological Research

Volumn 39, Issue 2, 1999, Pages 81-88

  Pascale, A ^a,b   Etcheberrigaray, R ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Alzheimer's disease; Calcium; Peripheral cells

Indexed keywords

AMYLOID BETA PROTEIN; CALCIUM BINDING PROTEIN; CALCIUM ION;

AGING; ALZHEIMER DISEASE; CALCIUM HOMEOSTASIS; CELL MEMBRANE; CLINICAL FEATURE; ENDOPLASMIC RETICULUM; HUMAN; MITOCHONDRION; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

EID: 0033082199     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1006/phrs.1998.0411     Document Type: Article

References (63)

1. Mattson MP. Calcium as sculptor and destroyer of neuronal circuitry. Exp Gerontol 1992; 27: 29-49.
2. 2+ signaling and crosstalk in stimulus secretion coupling. Biochim Biophys Acta 1993; 1154: 105-56.
3. Catterall WA. Structure and function of voltage-gated ion channels. Annu Rev Biochem 1995; 64: 493-531.
4. Abdel-Latif AA. Calcium-mobilizing receptors, polyphosphoinositides, and the generation of second messengers. Pharmacol Rev 1986; 38: 227-72.
5. Rasmussen H. The calcium messenger. N Engl J Med 1986; 314: 1094-101.
6. 2+ store: A view from the lumen. Trends Biochem Sci 1988; 23: 10-14.
7. Volpe P, Krause KH, Hashimoto S, Zarzatto F, Pozzan T, Meldolesi J, Lew DP. 'Calciosome', a cytoplasmic organelle: The inositol 1,4,5-trisphosphate sensitive calcium store of non-muscle cells. Proc Natl Acad Sci 1988; 85: 1091-5.
8. 2+ homeostasis. Prog Neurobiol 1991; 37: 255-85.
9. Khachaturian ZS. Introduction and overview. Ann NY Acad Sci 1989; 568: 1-4.
10. Price DL, Sisodia S. Cellular and molecular biology of Alzheimer's disease and animal models. Annu Rev Med 1994; 45: 435-46.
11. Gasparini L, Racchi M, Binetti G, Trabucchi M, Solerte B, Alkon DL, Etcheberrigaray R, Gibson G, Blass J, Paoletti R, Govoni S. Peripheral markers in testing pathophysiological hypotheses and diagnosing Alzheimer's disease. FASEB J 1998; 12: 17-34.
12. Pascale A, Govoni S, Battaini F. Age-related alteration of PKC, a key enzyme in memory processes. Physiological and pathological examples. Mol Neurobiol 1998; 16: 49-62.
13. Bush AI, Beyreuther K, Masters CL. βA4 amyloid protein and its precursor in Alzheimer's disease. Pharmacol Ther 1992; 56: 97-117.
14. Cordell B. β-amyloid formation as a potential therapeutic target for Alzheimer's disease. Annu Rev Pharmacol Toxicol 1994; 34: 69-80.
15. Mattson MP, Cheng B, Davis D, Bryant K, Lieberburg I, Rydel RE. β-amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J Neurosci 1992; 12: 376-89.
16. 2+ homeostasis in Alzheimer's disease. TINS 1993; 16: 409-14.
17. Arispe N, Rojas E, Pollard HB. Alzheimer disease amyloid beta protein forms calcium channels in bilayer membranes: Blockade by tromethamine and aluminium. Proc Natl Acad Sci USA 1993; 90: 567-71.
18. Mattson MP, Furukawa K, Brace AJ, Mark RJ, Blanc E. Calcium homeostasis and free radical metabolism as convergence points in the pathophysiology of dementia. In: Molecular Models of Dementia. Tanzi R, Wasco W, eds. Clifton, NJ: Humana Press, 1997: 103.
19. Sagara Y, Daragusch R, Klier FG, Schubert D, Behl C. Increased antioxidant enzyme activity in amyloid beta protein-resistant cells. J Neurosci 1996; 16: 497-505.
20. Trojanowski JQ, Lee VM-Y. Phosphorylation of paired helical filament tau in Alzheimer's disease neurofibrillary lesions: Focusing on phophatases. FASEB J 1995; 9: 1570-6.
21. Peterson DA, Lucidi-Phillipi CA, Murphy DP, Ray J, Gage FH. FGF-2 protects layer II entorhinal glutamatergic neurons from axotomy-induced death. J Neurosci 1996; 16: 886-98.
22. Ueda K, Masliah E, Saitoh T, Bakalis SL, Scoble H, Kosik KS. Alz-50 recognizes a phosphorylated epitope in tau. J Neurosci 1990; 10: 3295-304.
23. 28k: A potential neuroprotective protein. Neurode-generation 1994; 3: 1-20.
24. Mattson MP, Cheng B, Culwell A, Esch F, Lieberburg I, Rydel RE. Evidence for excitoprotective and intraneuronal calcium-regulating roles for secreted forms of β-amyloid precursor protein. Neuron 1993; 10: 243-54.
25. 2+ homeostasis in lymphoblasts from patients with lateonset Alzheimer's disease. Alzheimer's Dis Assoc Disord 1997; 11: 220-7.
26. Etcheberrigaray R, Ito E, Oka K, Tofel-Grehl B, Gibson GE, Alkon DL. Potassium channel dysfunction in fibroblasts identifies patients with Alzheimer's disease. Proc Natl Acad Sci USA 1993; 90: 8209-13.
27. + channels. Science 1994; 264: 276-9.
28. Etcheberrigaray R, Alkon DL. Potassium channels and calcium release: Pathophysiological and diagnostic implications for Alzheimer's disease. In: Molecular Models of Dementia. Tanzi R, Wasco W, eds. Clifton, NJ: Humana Press, 1997: 239.
29. Etcheberrigaray R, Alkon DL. Potassium channels and internal calcium release: Relevance for memory storage and Alzheimer's disease. In: Pharmacological Control of Calcium and Potassium Homeostasis. Godfraind T et al. eds. Netherlands: Kluwer Academic Publishers and Fondazione Giovanni Lorenzini, 1995: 227.
30. Huang HM, Martins R, Gandy S, Etcheberrigaray R, Ito E, Alkon DL, Blass J, Gibon G. Use of cultured fibroblasts in elucidating the pathophysiology and diagnosis of Alzheimer's disease. Ann NY Acad Sci 1994; 747: 225-44.
31. Hirashima N, Etcheberrigaray R, Bergamaschi S, Racchi M, Battaini F, Binetti G, Govoni S, Alkon DL. Calcium responses in human fibroblasts: A diagnostic molecular profile for Alzheimer's disease. Neurobiol Aging 1996; 17: 549-55.
32. Huang HM, Lin TA, Sun GY, Gibson GE. Increased inositol 1,4,5-trisphosphate accumulation correlates with an up-regulation of bradykinin receptors in Alzheimer's disease. J Neurochem 1995; 64: 761-6.
33. Bruel A, Cherqui G, Columbelli S, Margelin D, Roudier M, Sinet PM, Prieur M, Perignon JL, Delabar J. Reduced protein kinase C activity in sporadic Alzheimer's disease fibroblasts. Neurosci Lett 1991; 133: 89-92.
34. Govoni S, Bergamaschi S, Racchi M, Battaini F, Binetti G, Bianchetti A, Trabucchi M. Cytosol protein kinase C down-regulation in fibroblasts from Alzheimer's disease patients. Neurology 1993; 43: 2581-6.
35. 3 formation by protein kinase C in human fibroblasts. Life Sci 1996; 59: 1533-43.
36. 2+], transients are similar in fibroblasts from normal and Alzheimer's donors. Neurobiol Aging 1991; 13: 33-8.
37. Huang H-M, Toral-Barza L, Thaler H, Ofel-Grehl, Gibson GE. Inositol phosphates and intracellular calcium after bradykinin stimulation in fibroblasts from young, normal aged and Alzheimer donors. Neurobiol Aging 1991; 12: 469-73.
38. Tatebayshi Y, Takeda M, Kashiwagi Y, Okochi M, Kurumadani T, Sekiyama A, Kanayama G, Hariguchi S, Nishimura T. Cell-cycle-dependent abnormal calcium response in fibroblasts from patients with familial Alzheimer's disease. Dementia 1995; 6: 9-16.
39. Racchi M, Ianna P, Binetti G, Trabucchi M, Govoni S. Bradykinin induced amyloid precursor protein secretion: A protein kinase C independent mechanism that is not altered in sporadic Alzheimer's disease fibroblasts. Biochem J 1998; 330: 1271-5.
40. Spindel ER, Giladi E, Segerson TP, Nagalla S. Bombesin-like peptides: Of ligands and receptors. Recent Prog Horm Res 1993; 48: 365-91.
41. 2+ mobilization is altered in fibroblasts from patients with Alzheimer disease. Proc Natl Acad Sci USA 1994; 91: 534-8.
42. Gibson GE, Vestling M, Zhang H, Szolosi S, Alkon D, Lannfelt L, Gandy S, Cowburn RF. Abnormalities in Alzheimer's disease fibroblasts bearing the APP670/671 mutation. Neurobiol Aging 1997; 18: 573-80.
43. Adunsky A, Baram D, Hershkowitz M, Mekori YA. Increased cytosolic free calcium in lymphocytes of Alzheimer patients. J Immunol 1991; 33: 167-72.
44. Eckert A, Hartmann H, Muller WE. β-amyloid protein enhances the mitogen-induced calcium response in circulating human lymphocytes. FEBS Lett 1993; 330: 49-52.
45. 2+] in mononuclear blood cells from demented patients and healthy controls. Eur Arch Psychiatry Clin Neurosci 1994; 243: 224-8.
46. Eckert A, Hartmann H, Forstl H, Muller WE. Alterations of intracellular calcium regulation during aging and Alzheimer's disease in nonneuronal cells. Life Sci 1994; 55: 2019-29.
47. + lymphocytes in Alzheimer's disease and in older persons with down's syndrome. Neurobiol Aging 1993; 14: 177-85.
48. +-channels in Alzheimer's disease. J Psychiatry Res 1996; 30: 217-27.
49. Le Quan Sang KH, Mignot E, Gilbert JC, Huguet R, Aquino JP, Reigner O, Devynck MA. Platelet cytosolic free-calcium concentration increased in aging and Alzheimer's disease. Biol Psychiatry 1993; 33: 391-3.
50. Gardella JE, Ghiso J, Gorgone GA, Marratta D, Kaplan AP, Frangione B, Gorevic PD. Intact Alzheimer amyloid precursor protein (APP) is present in platelet membranes and is encoded by platelet mRNA. Biochem Biophys Res Comm 1990; 173: 1293-8.
51. Sheehan JP, Swerdlow RH, Miller SW, Davis RE, Parks JK, Parker WD, Tuttle JB. Calcium homeostasis and reactive oxygen species production in cells transformed by mitochondria from individuals with sporadic Alzheimer's disease. J Neurosci 1997; 17: 4612-22.
52. Garlind A, Wiehager B, Winblad B, Fowler CJ. Intracellular inositol (1,4,5)-Trisphosphate receptor levels are preserved in Alzheimer's disease platelets. Neurobiol Aging 1997; 18: 559-61.
53. De Jonge MC, Traber J. Nimodipine: Cognition, aging, and degeneration. Clin Neuropharmacol 1993; 16: S25-S30.
54. Disterhoft JF, Thompson LT, Moyer JR Jr, Mogul DJ. Calcium-dependent after hyperpolarization and learning in young and aging hippocampus. Life Sci 1996; 59: 413-20.
55. Tollefson GD. Short-term effects of the calcium channel blocker nimodipine (bay-e-9736) in the management of primary degenerative dementia. Biol Psychiatry 1990; 27: 1133-42.
56. Fritze J, Walden J. Clinical findings with nimodipine in dementia: Test of the calcium hypothesis. J Neural Transm Suppl 1995; 46: 439-53.
57. De Vry J, Fritze J, Post RM. The management of coexisting depression in patients with dementia: Potential of calcium channel antagonists. Clin Neuropharmacol 1997; 20: 22-35.
58. Kristian T, Katsura, Siesjo BK. Ionic metabolism in cerebral ischemia. In: Pharmacological Control of Calcium and Potassium Homeostasis: Biological, Therapeutical and Clinical Aspects. Godfraind T, Mancia G, Abbracchio MP, Aguilar-Bryan L, Govoni S, eds. Netherlands: Kluwer Academic Publishers and Fondazione Giovanni Lorenzini, 1995: 199.
59. Choi DW. Calcium: Still center-stage in hypoxicischemic neuronal death. Trends Neurosci 1995; 18: 58-60.
60. American Nimodipine Study Group. Clinical trial of nimodipine in acute ischemic stroke. Stroke 1992; 23: 3-8.
61. Wityk RJ, Stern BJ. Ischemic stroke: Today and tomorrow. Crit Care Med 1994; 22: 1278-93.
62. Wei H, Perry DC. Dantrolene is cytoprotective in two models of neuronal cell death. J Neurochem 1996; 67: 2390-8.
63. 2+ release from intracellular stores in cultured cerebral cortical neurons. J Neurochem 1991; 56: 1075-8.